Insulin aspart is under clinical development by Biocon and currently in Pre-Registration for Type 2 Diabetes. According to GlobalData, Pre-Registration drugs for Type 2 Diabetes have a 93% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Insulin aspart’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Insulin aspart overview
Insulin aspart recombinant (Kixelle/Kirsty) is a rapid-acting human insulin analog acts as antidiabetic agent. It is produced by employing recombinant DNA technology on Pichia pastoris. It is formulated as solution for subcutaneous, intravenous route of administration. Kixelle is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.
Biosimilar of insulin aspart is under development for the treatment of type 2 diabetes. It is administered through subcutaneous and intravenous route. It is a rapid acting drug candidate. It works by stabilizing the insulin that is disturbed during the disease. It was under development for the treatment of type 1 diabetes.
Biocon is a biopharmaceutical company that focuses on the research and development of therapies for the treatment of chronic conditions such as cancer, diabetes and autoimmune diseases. It offers a range of active pharmaceutical ingredients (APIs), branded formulations, complex biologics and biosimilars including monoclonal antibodies (MAbs), rh-Insulin and insulin analogs. The company also provides services including contract manufacturing, drug licensing, research, development and manufacturing of small and large molecules for biotechnology and pharmaceutical companies across the world. It has a manufacturing facility and R&D center at BioXcell, Malaysia. It operates overseas offices in the UK, Ireland, the US, Switzerland, Dubai, and Malaysia. Biocon is headquartered in Bangalore, Karnataka, India.
For a complete picture of Insulin aspart’s drug-specific PTSR and LoA scores, buy the report here.